These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29132405)

  • 1. Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment.
    Pakpour S; Bhanvadia A; Zhu R; Amarnani A; Gibbons SM; Gurry T; Alm EJ; Martello LA
    Microbiome; 2017 Nov; 5(1):148. PubMed ID: 29132405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.
    Lesniak NA; Schubert AM; Sinani H; Schloss PD
    mSphere; 2021 May; 6(3):. PubMed ID: 33952668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 5. Gut metabolites predict Clostridioides difficile recurrence.
    Dawkins JJ; Allegretti JR; Gibson TE; McClure E; Delaney M; Bry L; Gerber GK
    Microbiome; 2022 Jun; 10(1):87. PubMed ID: 35681218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis.
    Lee AA; Rao K; Limsrivilai J; Gillilland M; Malamet B; Briggs E; Young VB; Higgins PDR
    Inflamm Bowel Dis; 2020 Oct; 26(11):1748-1758. PubMed ID: 31971239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary Xanthan Gum Alters Antibiotic Efficacy against the Murine Gut Microbiota and Attenuates
    Schnizlein MK; Vendrov KC; Edwards SJ; Martens EC; Young VB
    mSphere; 2020 Jan; 5(1):. PubMed ID: 31915217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice.
    Tomkovich S; Stough JMA; Bishop L; Schloss PD
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33087520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection.
    Seekatz AM; Rao K; Santhosh K; Young VB
    Genome Med; 2016 Apr; 8(1):47. PubMed ID: 27121861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance.
    Tomkovich S; Taylor A; King J; Colovas J; Bishop L; McBride K; Royzenblat S; Lesniak NA; Bergin IL; Schloss PD
    mSphere; 2021 Oct; 6(5):e0062921. PubMed ID: 34585964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.
    Zhang L; Dong D; Jiang C; Li Z; Wang X; Peng Y
    Anaerobe; 2015 Aug; 34():1-7. PubMed ID: 25817005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
    Allegretti JR; Kao D; Phelps E; Roach B; Smith J; Ganapini VC; Kassam Z; Xu H; Fischer M
    Dig Dis Sci; 2019 Jun; 64(6):1668-1671. PubMed ID: 30632052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiota-based markers predictive of development of Clostridioides difficile infection.
    Berkell M; Mysara M; Xavier BB; van Werkhoven CH; Monsieurs P; Lammens C; Ducher A; Vehreschild MJGT; Goossens H; de Gunzburg J; Bonten MJM; Malhotra-Kumar S;
    Nat Commun; 2021 Apr; 12(1):2241. PubMed ID: 33854066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
    Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
    Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.
    Gómez S; Chaves F; Orellana MA
    Anaerobe; 2017 Dec; 48():147-151. PubMed ID: 28830842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls.
    Schubert AM; Rogers MA; Ring C; Mogle J; Petrosino JP; Young VB; Aronoff DM; Schloss PD
    mBio; 2014 May; 5(3):e01021-14. PubMed ID: 24803517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.